Dengue Fever Overview

Dengue fever is a disease caused by four dengue viruses spread by the Aedes aegypti mosquito. The Center for Disease Control and Prevention (CDC) estimates that at least 400 million cases of dengue fever occur across the globe every year. It is also known as break bone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms.

“Dengue Fever Pipeline Insight, 2022“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Fever Market. 

The Dengue Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Dengue Fever Pipeline Report:

• Companies across the globe are diligently working toward developing novel Dengue Fever treatment therapies with a considerable amount of success over the years. Dengue Fever Key players such as – Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Janssen Research & Development, Visterra, Merck & Co., Takeda, and others, are developing therapies for the Dengue Fever treatment 

• Dengue Fever Emerging therapies such as – anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue Fever market in the coming years.   
• In December 2021, Janssen Research & Development initiated a Phase IIa, Randomized, Doubleblind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ64281802 in Participants With Confirmed Dengue Fever. 

Dengue Fever Pipeline Therapeutics Assessment

• Dengue Fever Assessment by Product Type
• Dengue Fever By Stage and Product Type
• Dengue Fever Assessment by Route of Administration
• Dengue Fever By Stage and Route of Administration
• Dengue Fever Assessment by Molecule Type
• Dengue Fever by Stage and Molecule Type

DelveInsight’s Dengue Fever Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Dengue Fever Drugs Under Different Phases of Clinical Development Include:

• Research programme: anti-RNA virus therapeutics – Kino Pharma
• ABX220: Abivax
• Infectious diseases therapeutics Programme: Plex Pharmaceuticals
• CDX DENV: Codagenix
• AT-752: Atea Pharmaceuticals
• LD vehicle-GNP: Emergex Vaccines
• VIS513: Visterra
• JNJ-64281802: Janssen Research & Development
• TV003: Merck & Co.
• V 503: Takeda 

Get a Free Sample PDF Report to know more about Dengue Fever Pipeline Assessment- https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight

Dengue Fever Pipeline Analysis:

The Dengue Fever pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Dengue Fever treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever Treatment.
• Dengue Fever key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dengue Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue Fever market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Dengue Fever product details are provided in the report. Download the Dengue Fever pipeline report to learn more about the emerging Dengue Fever therapies

Dengue Fever Pipeline Market Drivers

• Fastest spreading mosquito-borne viral disease
• Search of novel tools and innovative strategies to interrupt transmission of dengue
• Integration of vector management approaches is encouraged

Dengue Fever Pipeline Market Barriers

• Challenging research due to multiple stereotypes
• Disease risks may change and shift with climate change in tropical and subtropical areas

Scope of Dengue Fever Pipeline Drug Insight    

• Coverage: Global
• Key Dengue Fever Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Janssen Research & Development, Visterra, Merck & Co., Takeda, and others
• Key Dengue Fever Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others
• Dengue Fever Therapeutic Assessment: Dengue Fever current marketed and Dengue Fever emerging therapies
• Dengue Fever Market Dynamics: Dengue Fever market drivers and Dengue Fever market barriers 

Request for Sample PDF Report for Dengue Fever Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Dengue Fever drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/